期刊文献+

潜变量增长混合模型在慢性心衰患者生理症状变化轨迹研究中的应用

Application of Latent Growth Mixture Modeling in the Study of the Trajectory of Physiological Symptoms in Patients with Chronic Heart Failure
下载PDF
导出
摘要 目的分析慢性心力衰竭(chronic heart failure,CHF)患者报告结局(patient-reported outcomes,PRO)纵向随访数据,探索不同潜在亚类及个体发展轨迹。方法纳入2017年5月-2019年6月山西三所三甲医院的286例CHF患者,选取患者住院时、出院后6、12、18、24月的CHF-PRO数据,对患者的生理领域及躯体状况、食欲睡眠和身体独立三个维度拟合潜变量增长混合模型,识别异质性亚类及个体轨迹变化规律。结果生理领域和各维度变化轨迹存在差异。生理领域中3类二次函数模型最优,第一潜在亚类随时间先下降后上升,第二、三潜在亚类随时间先上升后趋于平稳。躯体症状维度中3类非定义曲线模型最优,3个潜在亚类都是先上升后趋于平稳。食欲睡眠维度2类二次函数模型最优,第一、二潜在亚类随时间先上升,之后第二潜在亚类出现下降趋势。身体独立维度2个潜在亚类整体好转,最后均趋于平稳。结论患者出院后CHF-PRO的生理领域及各维度水平变化存在不同亚类及个体发展轨迹,对患者给予针对性干预措施具有重要作用。 Objective The longitudinal follow-up data of patient-reported outcomes of patients with chronic heart failure were analyzed to explore different latent classes and individual development trajectories.Methods A total of 286 patients with CHF were consecutively enrolled from the top three hospitals in Shanxi Province from May 2017 to June 2019.We used data from baseline and 6,12,18 and 24 months of follow-up.Physiological domain,somatization,appetite sleep,independence dimensions were fitted to identify heterogeneous subgroups and patterns of change in individual trajectories.Results There were differences in the trajectories of physiological domains and each dimension.In the domain of physiology,the 3-class of quadratic model was the best-fitting model.The first latent class showed a trend of decline first and then elevation over time,the second and third subgroups showed trends of elevation first and then stable change.The 3-class of undefined curve model in the somatic symptom was the best-fitting model,and the three latent subgroups demonstrated elevation first and then stable change over time.The two-class of quadratic model of appetite sleep was best-fitting model.The first and second subgroups showed trends of elevation first and then the second latent subgroup showed a trend of decreasing over time.The two subgroups of independence improved overall,and finally stabilized.Conclusion There are different subgroups and individual development trajectories in the physiological domains and various dimensions of CHF-PRO,which plays an important role in providing targeted interventions to the patients.
作者 丁凤琴 田晶 孟冰霞 韩琳艾 李靓 韩清华 张岩波 Ding Fengqin;Tian Jing;Meng Bingxia(Department of Epidemiology and Health Statistics,School of Public Health,Shanxi Medical University(030001),Taiyuan)
出处 《中国卫生统计》 CSCD 北大核心 2023年第4期482-486,共5页 Chinese Journal of Health Statistics
基金 国家自然科学基金(81872714) 山西省重点实验室(201805D111006)。
关键词 慢性心力衰竭 患者报告结局 生理症状 潜变量增长混合模型 Chronic heart failure Patients report outcomes Physiological Symptoms Latent growth mixture model
  • 相关文献

参考文献5

二级参考文献48

  • 1托伐普坦临床研究协作组,张健,朱文玲.常规治疗基础上联用托伐普坦片治疗心原性水肿的有效性和安全性的多中心随机、双盲、安慰剂对照研究[J].中华心力衰竭和心肌病杂志(中英文),2017,1(1):15-21. 被引量:26
  • 2林丰勋.心理学纵向研究方法的新进展[J].济南大学学报(社会科学版),2005,15(5):79-82. 被引量:14
  • 3刘红云.如何描述发展趋势的差异:潜变量混合增长模型[J].心理科学进展,2007,15(3):539-544. 被引量:35
  • 4Wilke R J, Burke L B, Erickson P. Measuring treatment impact: a re- view of patient-- reported outcomes and other efficacy endpoints in ap- proved product labels[J]. Control Clin Trials, 2004,25 :535--552.
  • 5Acquadro C, Berzon R, Dubois D, Leidy N K, et al. PRO Harmo- nization Group: Incorporating the patient's perspective into clrug de- velopment and communication: an ad hoe task force report of the Patient--reported Outcomes(PRO) Harmonization Group meeting at theFood and Drug Administration, February 16,2001[J]. Value in Health,2003,6(5) :522--531.
  • 6The ERIQA Group: Assessing Treatment Impact Using Patient--Reported Outcomes (PROs) : Challenges in Study Design, Conduct and Analysis. Meeting Report (Paris, May 10--11, 2004)[J]. Pa- tient- Reported Outcomes Newsletter, 2005, 3(Special) : 1-- 16.
  • 7U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Re- search, Center for Devices and Radiologieal Health. Guidance for Indus- try--Patient Reported Outcome Measures: Use in Medical Product De- velopment to Support Labeling Claims[EB/OL]. (2009--03--07)[2011 12-- 121. http://www, hqlo. corn/content/4/1/79.
  • 8Lynda C Doward, Ari Gnanasakthy, Mary G Baker. Patient repor- ted outcomes: looking beyond the label claim. Health and Quality of Life Outcomes[J]. Health Qual Life Outcomes, 2010,8:89.
  • 9Clare Bradley. Feedback on the FDA's February 2006 draft guid- ance on Patient Reported Outcome (PRO) measures from a devel- oper of PRO Measures[J]. Health and Quality of Life Outcomes, 2006,4:78.
  • 10Department of Health. Our Health, Our Care, Our Say: A New Direction for Community Services[J]. White Paper, London , 2006:1--236.

共引文献5821

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部